Skip to main content

Greater Epigenetic Age Seen in Patients With Pediatric-Onset MS

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on June 17, 2025.

via HealthDay

TUESDAY, June 17, 2025 -- Individuals with pediatric-onset multiple sclerosis (POMS) have greater epigenetic age and age acceleration residual (AAR) compared with age-similar controls, according to a study published online June 3 in Neurology.

Christopher Goyne, M.D., from the University of California, San Diego, and colleagues compared epigenetic age in participants with POMS and age-similar controls in a multicenter case-control analysis of a prospectively collected set of whole-blood DNA samples and clinical data. Epigenetic age was calculated based on four established algorithms; using multivariate regression analysis, epigenetic age and AAR were compared for participants with POMS and controls (125 [mean age, 15.7 years] and 145 [mean age, 15.3 years], respectively).

The researchers found that after adjustment for age, sex, body mass index, tobacco exposure, and socioeconomic status, cases had greater epigenetic age and AAR than controls. For two of the four epigenetic clocks used, this difference was statistically significant (Hannum β, 1.50 years; PhenoAge β, 1.72 years).

"Aging isn't something we think of affecting teenagers. But these kids are accumulating cellular damage that may not show up clinically until years later, when they suddenly transition from doing fine to disease progression in their 30s," senior author Jennifer S. Graves, M.D., Ph.D., also from the University of California, San Diego, said in a statement. "It is a significant finding to see this accelerated aging in children. If we can understand the interplay between the immune system, the brain and aging -- and break that open -- we might be able to put MS into full remission in the future."

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Helping Others Linked to Higher Level of Cognitive Function

THURSDAY, Aug. 21, 2025 -- Helping others, both via formal volunteering and informal helping, is associated with higher levels of cognitive function and slower cognitive decline...

TAR-200 Monotherapy Promising for BCG-Unresponsive Bladder Cancer

THURSDAY, Aug. 21, 2025 -- For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), an intravesical...

Work-Related Income Drops for Parents of Children Diagnosed With Type 1 Diabetes

THURSDAY, Aug. 21, 2025 -- Work-related income decreases sharply for mothers and fathers of children diagnosed with type 1 diabetes, with similar effects across sociodemographic...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.